166 related articles for article (PubMed ID: 37268059)
1. The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual.
Angelis A; Harker M; Cairns J; Seo MK; Legood R; Miners A; Wiseman V; Chalkidou K; Grieve R; Briggs A
Value Health; 2023 Oct; 26(10):1503-1509. PubMed ID: 37268059
[TBL] [Abstract][Full Text] [Related]
2. Some inconsistencies in NICE's consideration of social values.
Paulden M; O'Mahony JF; Culyer AJ; McCabe C
Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
[TBL] [Abstract][Full Text] [Related]
3. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
Charlton V
Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
[TBL] [Abstract][Full Text] [Related]
4. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
Charlton V
Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
[TBL] [Abstract][Full Text] [Related]
5. The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products.
Lee D; McCarthy G; Saeed O; Allen R; Malottki K; Chandler F
Pharmacoecon Open; 2023 Mar; 7(2):175-187. PubMed ID: 36315388
[TBL] [Abstract][Full Text] [Related]
6. Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis.
Hale G; Morris J; Barker-Yip J
J Comp Eff Res; 2023 Nov; 12(11):e230093. PubMed ID: 37724717
[No Abstract] [Full Text] [Related]
7. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
de Folter J; Trusheim M; Jonsson P; Garner S
Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
[TBL] [Abstract][Full Text] [Related]
8. NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests.
O'Mahony JF; Paulden M; McCabe C
Pharmacoeconomics; 2021 Feb; 39(2):139-146. PubMed ID: 33462758
[TBL] [Abstract][Full Text] [Related]
9. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
O'Mahony JF; Paulden M
Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
[TBL] [Abstract][Full Text] [Related]
10. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
11. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
12. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Tikhonova IA; Hoyle MW; Snowsill TM; Cooper C; Varley-Campbell JL; Rudin CE; Mujica Mota RE
Pharmacoeconomics; 2017 Mar; 35(3):363-373. PubMed ID: 27752999
[TBL] [Abstract][Full Text] [Related]
14. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
Charlton V
Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
[TBL] [Abstract][Full Text] [Related]
15. Capturing what matters: updating NICE methods guidance on measuring and valuing health.
Dawoud D; Lamb A; Moore A; Bregman C; Rupniewska E; Paling T; Wolfram V; Lovett RES; Dent R
Qual Life Res; 2022 Jul; 31(7):2167-2173. PubMed ID: 35247152
[TBL] [Abstract][Full Text] [Related]
16. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
Sculpher M; Palmer S
Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
[TBL] [Abstract][Full Text] [Related]
17. Closing the loop between horizon scanning and health technology assessment - an overview of topics submitted for appraisal in England.
Khan SK; Gonzalez-Moral SG; Lanyi K; Ogunbayo D; Craig D
Int J Technol Assess Health Care; 2023 Sep; 39(1):e64. PubMed ID: 37690810
[TBL] [Abstract][Full Text] [Related]
18. Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.
Lord J; Willis S; Eatock J; Tappenden P; Trapero-Bertran M; Miners A; Crossan C; Westby M; Anagnostou A; Taylor S; Mavranezouli I; Wonderling D; Alderson P; Ruiz F
Health Technol Assess; 2013 Dec; 17(58):v-vi, 1-192. PubMed ID: 24325843
[TBL] [Abstract][Full Text] [Related]
19. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
Charlton V
J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
[TBL] [Abstract][Full Text] [Related]
20. Modifying NICE's Approach to Equity Weighting.
Paulden M; McCabe C
Pharmacoeconomics; 2021 Feb; 39(2):147-160. PubMed ID: 33517512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
